Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.

Int J Chron Obstruct Pulmon Dis · 2012 · PMC3430121 · PMID 22973092

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

A numerical trend in favor of NVA237 on Day 1 was also observed for leg discomfort.

also in 723 other papers

showed a trendno p-value reported

Symptoms Daily symptoms of patients showed a trend towards a higher number of patients with no or mild symptoms following NVA237 treatment compared with symptoms resulting from placebo administration on most treatment days.

also in 33,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.